Explore comprehensive STRO stock forecasts for 2025, 2030, 2035, 2040, 2045, 2050, and 2060, along with price targets, predictions, and expert insights. Learn about Sutro Biopharma Inc.’s (STRO) innovative therapies and potential growth opportunities.
Key Takeaway: Sutro Biopharma Stock Forecast by 11 analysts with 52 weeks price forecasts for Sutro Biopharma stock have an average target of 12.00, with a low estimate of 8.30 and a high estimate of 18.50 The average target predicts an increase of 207.00% from the current stock price of 4.26.
Read: Amazon Stock Forecast 2025, 2030, 2040, 2050 Price Target
Table of Contents
Sutro Biopharma, Inc. Common Stock (STRO) Company outlook
Sutro Biopharma (STRO: NASDAQ)is a California-based biopharmaceutical company known for its innovative protein therapeutics platform, XpressCF®. They specialize in developing a wide range of protein-based drugs, particularly focusing on oncology with lead candidate STRO-001, an antibody-drug conjugate targeting CD74. Collaborations with major pharmaceutical companies further strengthen their position in the industry.
Company Profile
| Company | Sutro Biopharma, Inc. |
|---|---|
| Ticker | STRO (NASDAQ) |
| Sector | Healthcare (1209) |
| Industry | Biotechnology (699) |
| Phone | 650-392-8412 |
| Address | 310 Utah Avenue, Suite 150, South San Francisco, CA |
| Employees | 141 |
| @SutroBio | |
| Next Earnings Date | 2024-06-06 |
| Website | www.sutrobio.com |
Read: UNH STOCK FORECAST 2025, 2030, 2040: Is UNH a buy or a sell?
Sutro Biopharma Inc (STRO) Fundamental Analysis
| Previous Close | $4.1500 |
| Open | $4.1800 |
| Day’s Range | $3.9900 – $4.1900 |
| 52 Week Range | $2.0100 – $6.1300 |
| Volume | 388,410 |
| Avg. Volume | $327.995M |
| Market Cap (intraday) | $327.995M |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N-A |
| EPS (TTM) | -$1.8800 |
| Forward Dividend & Yield | N-A |
| 1y Target Est | $12.30 |
Sutro Biopharma Inc (STRO) Historical Chart by Trading View
Read More: CRBG stock price prediction 2024, 2025, 2030, 2040, 2050, 2060 Growth
Recent News about Sutro Biopharma (STRO)
- TipRanks: Bank of America Predicts Nearly 200% Growth for Two ‘Strong Buy‘ Stocks
- GlobeNewswire: Sutro Biopharma Releases Q1 2024 Financial Results and Key Business Milestones
- Zacks: Analysts Anticipate Earnings Decline for Sutro Biopharma (STRO): Key Factors to Monitor
- Simply Wall St.: Sutro Biopharma (NASDAQ: STRO) Investors Face Unprofitable Three-Year Period
- Zacks: AnaptysBio (ANAB) Jumps 14.3%: Is More Growth Ahead?
- GlobeNewswire: Sutro Biopharma Begins Randomized Phase (Part 2) of REFRαME-O1 Trial
- Simply Wall St.: Analysts Significantly Lower EPS Projections for Sutro Biopharma (NASDAQ: STRO)
- GlobeNewswire: Sutro Biopharma Announces $75 Million Underwritten Offering Pricing
- GuruFocus.com: Mixed Results in Sutro Biopharma Inc (STRO) Earnings Amid Strategic Developments
- Zacks: Sutro Biopharma (STRO) Exceeds Q4 Earnings and Revenue Expectations
- Sutro Biopharma Unveils Full Year 2023 Financial Results and Future Business Highlights
Long-term STRO Stock Price Forecast for 2025, 2030, 2035, 2040, 2045, 2050, and 2060
Based on the latest long-term forecast, Sutro Biopharma Inc (STRO) Stock price will reach $5.75 in 2024, hit $12.75 by the end of 2025, $20 by 2030, $35 by 2035, $50 by 2040, $70 by 2045, $100 by 2050, and $150 by 2060. See the forecasted yearly prices until 2060 of the STRO stock below:
| Year | Prediction | Change% |
|---|---|---|
| 2024 | $5.75 | 7.74% |
| 2025 | $12.57 | 213.47% |
| 2030 | $20.00 | 59.10% |
| 2035 | $35.00 | 75.00% |
| 2040 | $50.00 | 42.86% |
| 2045 | $70.00 | 40.00% |
| 2050 | $100.00 | 42.86% |
| 2060 | $150.00 | 50.00% |
Continue Reading: SMCI Stock Price Prediction 2024, 2025, 2030 to 2050: A Semiconductor Powerhouse
STRO Stock Forecast 2024
Analysts estimate that Sutro Biopharma Inc. (STRO) share price could reach $12.65 by May 25, 2025. The average Sutro Biopharma stock forecast predicts a potential upside of 219.87% from the current STRO share price of $3.93. Recently, Sutro Biopharma’s stock opened at $4.06, based on a 14-day average.
STRO Stock Forecast 2025
Sutro Biopharma, Inc. (STRO) stock is projected to have a whopping increase of 24.1% anticipated to reach an average price target of $10.50 per share by May 11, 2025. The STRO forecasts range from high predictions to low estimates ranging between $7.05 to $22 from its current valuation.
STRO Stock Forecast 2030
Sutro Biopharma Inc. Stock (STRO) forecast is anticipated to reach an average price target of $13.56 in 2030, with a high prediction of $20 and a low forecast of $7.81 a 59.10% growth keeping its past 10 years of annual growth.
STRO Stock Forecast 2040
Sutro Biopharma Inc (STRO) stock is projected to experience significant growth in 2040, with an average price target of $45.25, representing a +42.86% high price prediction of $50 per share, and a low forecast of $28.145 from its current price.
STRO Stock Forecast 2050
Long-term Sutro Biopharma Inc (STRO) price prediction forecasts a potential upside of 92.86% and is expected to reach an average price target of $100 in 2050, with a high prediction of $105.28 and a low estimate of $81.81 from its current price.
STRO Stock Forecast 2060
Sutro Biopharma Inc. has a 50.00% upside potential, based on the analysts’ average price target will reach $140 per share in 2060 with a high forecast of $155.28 and a low estimate of $101.81. If this Sutro Biopharma Inc (STRO) stock price prediction for 2060 materializes, STRO stock will grow high from its current price.
Sutro Biopharma Inc (STRO) Price Prediction
- STRO Price Prediction 2025: Sutro Biopharma Inc (STRO) is predicted to hit ₹8.930, ranging between $8.770 and $15.200 which is a potential upside of 213.87% from its current price.
- STRO Price Prediction 2029: Sutro Biopharma Inc (STRO) is anticipated to reach $12.250, ranging from $15.975 to ₹26.500 which is a potential upside of 50.10% from its current price.
- STRO Price Prediction 2030: Sutro Biopharma Inc (STRO) is predicted to be around $13.163, ranging from $19.496 to $32.831 which is a potential upside of 59.10% from its current price.
- STRO Price Prediction 2040: Sutro Biopharma Inc (STRO) is anticipated to reach $16.200, ranging from $22.975 to ₹46.500 which is a potential upside of 42.86% from its current price.
- STRO Price Prediction 2045: Sutro Biopharma Inc (STRO) is assumed to be around $23.900, ranging from $44.01 to $51.57 which is a potential upside of 50% from its current price.
- STRO Price Prediction 2050: Sutro Biopharma Inc (STRO) is forecasted to be around $29.900, ranging from $49.01 to $59.55 which is a potential upside of 42.86% from its current price.
Conclusion and FAQ: Sutro Biopharma, Inc. Common Stock (NASDAQ: STRO)
Sutro Biopharma, Inc. (STRO) is expected to experience steady growth in its stock price from 2024 to 2060. Their focus on developing innovative cancer treatments and collaborations with major pharmaceutical companies signal promising prospects for investors. The earnings estimate for 2030 also suggests potential profitability. Overall, STRO appears poised for long-term success in the biotechnology industry.
What is the stock price prediction for Stro for 12 months?
According to MarketBeat, the average twelve-month price prediction for Sutro Biopharma (STRO) is $12.50, with a high target of $18.00 and a low target of $8.00.”
What is STRO Stock Price Today?
The current price of STRO as of 20 May 2024 is $4.56, reflecting a 13.72% increase in the past 24 hours.
Is Sutro Biopharma Inc. stock up/down today?
STRO stock has risen by 8.53% over the past week and 22.79% over the past month. However, Sutro Biopharma, Inc. has seen a 14.87% decrease over the last year.
What is Sutro Biopharma Inc. stock Forecast by Trading View?
Analysts’ opinions by Trading View on Sutro Biopharma, Inc. (STRO) future price range from a maximum estimate of $20.00 to a minimum estimate of $5.00.
Is STRO a good stock to buy?
Based on the ratings of 10 Wall Street analysts, Sutro Biopharma Inc. has a consensus rating of Strong Buy.
Who is the founder of Sutro Biopharma Inc.?
Sutro Biopharma was founded in 2003 under the name Fundamental Applied Biology. Its founder, William Newell, established the company.
What is the primary focus of Sutro Biopharma, Inc.?
Sutro Biopharma, Inc. is dedicated to transforming cancer treatment by developing meticulously engineered therapeutics, aiming to redefine scientific possibilities and provide precise solutions for patients fighting cancer.
What are Sutro Biopharma’s earning estimates for 2025?
The expected annual earnings per share for Sutro Biopharma, Inc. by December 31, 2030, are around $0.36.
What is the Sutro Biopharma, Inc. stock forecast?
Sutro Biopharma, Inc. stock prediction for 1 year from now: $ 12.75 (44.46%) Sutro Biopharma, Inc. stock forecast for 2025: $ 13.61 (49.92%) Sutro Biopharma, Inc. stock prediction for 2030: $ 20 (59.10%)
What is the Sutro Biopharma, Inc. stock prediction for 2025?
According to our Sutro Biopharma, Inc. stock prediction for 2025, STRO stock will be priced at $ 13.64 in 2025. This forecast depends on the stock’s average growth over the past 10 years.
What is the Sutro Biopharma, Inc. stock prediction for 2030?
The 8 analysts with 12-month Sutro Biopharma, Inc. stock prediction for 2030, STRO stock will be priced at the highest average target of $ 20 in 2030.
What is the Sutro Biopharma, Inc. stock prediction for 2040?
According to our Sutro Biopharma, Inc. stock forecast for 2040, STRO stock will be priced at $ 50 in 2025. This forecast depends on the stock’s average growth over the past 10 years.
What is the Sutro Biopharma, Inc. stock price forecast for 2035?
In 2035, the Sutro Biopharma, Inc. stock will reach $ 27.54 if it maintains its current 10-year average growth rate. If this STRO stock prediction for 2035 materializes, STRO stock will grow 35.51% from its current price.
Disclaimer: Stock forecasts and earnings estimates are subject to market volatility and should be considered speculative projections. Investors should conduct their research and consult with financial advisors before making investment decisions.
Ashish Dwivedi is the founder and chief editor of MoneyMystica, a top resource for finance, insurance, and share market insights. Driven by a passion for empowering individuals to make informed financial decisions, Ashish uses his extensive knowledge and practical experience to offer clear and actionable advice.
